SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB
Sign Up to like & getrecommendations! Published in 2022 at "Retina"
DOI: 10.1097/iae.0000000000003418
Abstract: Short-term brolucizumab therapy may result in anatomical benefits that are maintained for at least 6 months after switching to an alternative anti–vascular endothelial growth factor treatment while minimizing the risk of brolucizumab-related intraocular inflammation. Purpose:… read more here.
Keywords: treatment brolucizumab; brolucizumab; eyes decreased; interim treatment ... See more keywords